Dr. Martin King is an expert in prostate and gynecologic brachytherapy. He is interested in identifying therapeutic strategies that can improve quality of life for men receiving radiation therapy for prostate cancer. He is the principal investigator of a multi-center randomized controlled trial, which evaluates whether a novel second-generation anti-androgen Darolutamide can be utilized in place of traditional androgen deprivation therapy for preserving erectile function while not sacrificing the potential for long-term disease control. Patients will be stratified by a genomic classifier as well as extreme radiation dose-escalation (e.g. brachytherapy boost). Other areas of research interest involve radiation for radiorecurrent prostate cancer, as well as therapeutic de-escalation of combination radiation treatments for unfavorable risk prostate cancer. Dr. King is part of the Brachytherapy Clinical Operations Leadership Team, and is an assistant professor of radiation oncology at Harvard Medical School. He is heavily involved in teaching medical students and residents the radiotherapeutic management of prostate and gynecologic cancers with external beam radiation therapy and brachytherapy.